What is Halozyme Therapeutics's net change in cash?

Halozyme Therapeutics (HALO) reported net change in cash of $175.59M in Q1 2026.

How has Halozyme Therapeutics's net change in cash changed year-over-year?

Halozyme Therapeutics's net change in cash increased by 190.3% year-over-year, from $60.48M to $175.59M.

What is the long-term trend for Halozyme Therapeutics's net change in cash?

Over 2 years (2021 to 2024), Halozyme Therapeutics's net change in cash has grown at a -70.5% compound annual growth rate (CAGR), from -$28.98M to -$2.52M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Halozyme Therapeutics HALO Net Change in Cash

Net Change in Cash at other companies

West Pharmaceutical ServicesWST

-$269.9M-236%

BridgeBio PharmaBBIO

$309.88M+321%

Arrowhead ResearchARWR

-$14.12M-111%

AptarGroupATR

-$179.9M-83.6%

AbbVieABBV

$4.16B+1,293%

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's net change in cash?: Halozyme Therapeutics (HALO) reported net change in cash of $175.59M in Q1 2026.
How has Halozyme Therapeutics's net change in cash changed year-over-year?: Halozyme Therapeutics's net change in cash increased by 190.3% year-over-year, from $60.48M to $175.59M.
What is the long-term trend for Halozyme Therapeutics's net change in cash?: Over 2 years (2021 to 2024), Halozyme Therapeutics's net change in cash has grown at a -70.5% compound annual growth rate (CAGR), from -$28.98M to -$2.52M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.